
Please try another search
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Name | Age | Since | Title |
---|---|---|---|
Sukumar Nagendran | 55 | 2020 | President, Head of Research & Development and Director |
Sean P. Nolan | 55 | 2020 | CEO & Chairman |
Phillip B. Donenberg | 62 | 2020 | Independent Director |
Deborah Bilder | - | 2021 | Independent Scientific Advisory Board |
Paul B. Manning | 67 | 2020 | Board Observer |
Laura Sepp-Lorenzino | 62 | 2020 | Independent Director |
Sean Stalfort | 53 | 2023 | Independent Director |
Alison Long | 61 | 2023 | Independent Director |
David P. Dimmock | - | 2021 | Independent Scientific Advisory Board |
Gerald S. Lipshutz | - | 2021 | Independent Scientific Advisory Board |
Wendy K. Chung | 54 | 2021 | Independent Scientific Advisory Board |
Benedikt Schoser | - | 2021 | Member of Independent Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review